Latisse is a prescription strength serum intended to stimulate eyelash growth.
Get the long, lush lashes you’ve dreamed of having! Latisse™ lash serum (bimatoprost ophthalmic solution) 0.03% is the first and only brand name prescription treatment approved by the FDA for thin or sparse eyelashes, growing them longer, fuller and darker. With a simple one-a-day approach of one minute once a day to apply one drop per eyelid, you’ll see a visible difference in as little as 4 weeks with full results after 16 weeks.
After that, keep using Latisse 3-4 times per week to maintain your growth, and you’ll have eye-catching lashes even without mascara. No extensions or false lashes needed! Latisse is clinically proven to increase the thickness, darkness, and number of lashes gradually over time.
Please Note: Latisse® is available only with a prescription. Your consultation with our medical director and prescription are included in your first payment.
Ingredients: Active: bimatoprost 0.3 mg/mL; Preservative: benzalkonium chloride 0.05 mg/mL; Inactives: sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 – 7.8.
Make sure your lashes are clean and you’ve taken out your contact lenses. Put one drop of solution on one of the included sterile brushes. Sweep the brush along the base of the lash line on the upper eyelid only, as if applying liquid eyeliner. Discard brush and repeat on your other eye with another brush. Allow 15 minutes before inserting contact lenses or putting on makeup.
The cost of Latisse is $130 for a 4 week supply or $179 for a 10 week supply.
LATISSE® Professional Important Safety Information:
LATISSE® (bimatoprost ophthalmic solution) 0.03% . LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness. Important Safety Information Contraindications: LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients. Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure. Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent. Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients. There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes. LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. It is important to use LATISSE® solution as instructed, by placing one drop on the single-use-per-eye applicator. The bottle tip should not be allowed to contact any other surface since it could become contaminated. LATISSE® contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration. Adverse Reactions: The most frequently reported adverse reactions were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients. Postmarketing Experience: The following adverse reactions have been identified during postapproval use of LATISSE®: dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hordeolum, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), trichiasis, and vision blurred. For more information on LATISSE®, please see the accompanying full Prescribing Information.